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Abstract. Rhamnulose-1-phosphate aldolase from Thermotoga maritima (Rhu1PATm) has been recently cloned and 
characterized. This hyperthermophilic enzyme offers intriguing possibilities for practical catalysis. This is due to its high 
stability under extreme reaction conditions, such as high temperature or the presence of organic co-solvents. 
The Rhu1PATm potentiality in organic synthesis has been explored focusing on i) the reaction stereocontrol, ii) the 
possibility of combining it with other mesophilic enzymes in multienzyme systems and iii) its application to the synthesis 
of imino- and nitrocyclitols. 
In our study, Rhu1PATm diastereoselectivity was similar to the one reported by Rhu1PA from Escherichia coli 
(Rhu1PAEc).  
However, we observed significant differences for some aldehyde acceptors. Indeed, the diastereoselectivity control was 
not complete, since mixtures of L-threo (2R,3S; natural stereopreference) and D-erythro (2R,3R) diastereoisomers were 
obtained as described for Rhu1PAEc. Rhu1PATm was able to catalyse aldol reactions using nitroaldehydes and N-Cbz-
aminoaldehydes. Conversion of the selected nitroaldehydes was complete, leading to mixtures of L-threo and D-erythro 
diastereoisomers, in 95:5 and 75:25 ratios. When N-Cbz-aminoaldehydes were used, aldol reaction yields were lower and 
the stereoselectivity L-threo:D-erythro ranged between 32:68 to >95:5. 
Keywords: aldol reaction; azasugars; biocatalysis; cascade reactions; lyases; thermophilic enzymes 
Introduction 
Carbon-carbon (C–C) bond formation is one of the cornerstone reactions in synthetic organic chemistry.[1] In 
this sense, the catalytic asymmetric C-C bond formation by the aldol addition reaction has long been 
recognized as one of the most useful tools for construction of new C−C bonds, since concomitant with the bond 
forming process is the formation of one or two new stereocentres.[2] The use of enzymes as catalysts is a good 
alternative to non-enzymatic synthesis. This is because they provide a number of advantages, such as their 
ability to carry out the reactions under moderate conditions of temperature, pH and pressure, high efficiency 
and regio-, chemo- and stereoselectivity.[3] Enzymes also represent an environmentally attractive option 
because they can catalyse reactions in water and are biodegradable.[4] The high stereoselectivity of aldolases in 
C-C bond formation gives them a wide range of synthetic applications. Among the different families of 
aldolases, dihydroxyacetone phosphate (DHAP)-dependent aldolases have particularly attracted the attention of 
chemists. Furthermore, they have been extensively used in chemoenzymatic syntheses.[5] DHAP-dependent 
aldolases lead to the formation of two new stereocentres with a high degree of stereochemical control. Despite 
this well proven synthetic utility of aldolases, there are still few processes that have been developed at an 
industrial scale and none of them —to the best of our knowledge— used DHAP-dependent aldolases.[6] This is 
unfortunate, considering the recent advances in understanding the mechanism of aldolase catalysis. This has 
allowed the successful application of many different engineering approaches to alter the catalytic properties of 
aldolases such as stability, substrate specificity and stereoselectivity.[7]  
One of the main difficulties in applying these processes at an industrial scale is the lack of stability under 
reaction conditions. An approach to overcome this issue is the use of enzymes from extremophile 
microorganisms.[8] From a biocatalytical point of view, thermophilic and hyperthermophilic microorganisms 
have particularly attracted the attention, since they are sources of thermostable enzymes. Thermozymes display 
outstanding stability against high temperature, as well as against other denaturalization conditions, such as the 
presence of organic solvents, detergents or extreme pHs.[9] In this sense, we have recently described the 
heterologous expression of the rhamnulose-1-phosphate aldolase from Thermotoga maritima, its functional 
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characterization and preliminary synthetic properties.[10] This enzyme presented an optimum temperature at 95 
ºC and displayed a great stability to extreme reaction conditions, such as high temperatures (i.e., half-life of 
more than 3 hours at 115 ºC) and in the presence of different organic solvents. Furthermore, Rhu1PATm 
showed activity in a wide range of pH, with an optimum activity at pH at 8.0. A multienzyme system[11b] 
previously developed by the García-Junceda’s group, coupling the in situ phosphorylation of DHA with the 
aldolase catalysed aldol reaction, was successfully assayed with Rhu1PATm.[11] Rhu1PATm was assayed using 
the one-pot/two-steps protocol with four different aldehydes: L-lactaldehyde, benzyloxyacetaldehyde, 
phenylacetaldehyde and ethyl-3-methyl-4-oxocrotonate. Rhu1PATm was able to react with these four 
aldehydes at 45 ºC and 80 °C in combination with other mesophilic enzymes, in a one-pot/two-steps approach. 
The reactions were significantly faster at the highest temperature.[10]  
Herein, we describe the study of the synthetic utility of the Rhu1PATm, focusing on the stereocontrol of the 
aldol reaction, its ability to integrate with other mesophilic enzymes into multienzyme systems and, finally, its 
application to the synthesis of imino- and nitrocyclitols. 
Results and Discussion 
Study of the stereochemical outcome of Rhu1PATm catalysed reaction 
We first performed a study on the stereochemical outcome of the reaction catalysed by Rhu1PATm as a 
function of the temperature. To this end, the percentage of each diastereoisomer formed in the aldol addition 
reaction of DHAP to benzyloxyacetaldehyde 2 was measured at different times. Reactions were conducted at 4 
ºC, 25 ºC, 45 ºC and 80 ºC. 
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Scheme 1. Aldol addition reaction of DHAP (1) —in situ obtained by enzymatic phosphorylation of DHA— to 
benzyloxyacetaldehyde 2 catalysed by Rhu1PATm. 
As expected, the diasteroisomer L-threo (3R,4S), which is the one of the natural preference of the enzyme, 
was synthesized faster (i.e. kinetic product) than the D-erythro. In particular, this difference was highlighted at 
4 ºC due to the slowing down of the reaction rate (Figure 1A). In all temperatures assayed, the ratio 
threo:erythro decreased with the progress of the reaction, until reaching a plateau at 2:1 ratio (Figure 1). 
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Figure 1. Diastereoisomer L-threo:D-erythro ratio obtained in the aldol reaction of DHAP to 2 catalysed by Rhu1PATm at 
4 ºC (A; ∆), 25 ºC (A; ▲), 45 ºC (B; ○) and 80 ºC (B; ●). 
However, thermodynamic equilibrium was reached faster with the increase of temperature. A similar result 
was obtained when Rhu1PAEc was used with (R)-N-Cbz-2-aminohexanal as substrate. In this case, the 
diastereoisomer ratio obtained did not vary at different reaction temperatures. However, the L-threo:D-erythro 
ratio changed with the temperature when (R)-N-Cbz-2-aminopentanal or N-Cbz-2-amino-4-methylpentanal 
were used as acceptor substrates.[12] Thus, it cannot be excluded that the Rhu1PATm stereoselectivity could 
change with the temperature when using other aldehydes as substrates. 
Synthesis of nitrocyclitols mediated by Rhu1PATm 
Nitrocyclitols belong to the large family of cyclitols and are essentially found as synthetic precursors of 
aminocyclitols.[13] These amines are present in many pharmacologically significant compounds exhibiting 
antitumor, antibacterial, antifungal, antimalarial, and antiviral activities.[14] Consequently, in the last decade 
there has been an increasing demand for the development of appropriate synthetic procedures to prepare 
cyclitols as well as analogues with enhanced or more selective biological profiles.[15]  
Lemaire’s group reported a straightforward chemoenzymatic cascade to access nitro- and aminocyclitols. 
This process involved two stereoselective C-C bond formations. One was catalysed by an aldolase and the other 
was a spontaneous intramolecular Henry reaction.[16] Herein, we have studied the application of the Rhu1PATm 
in the context of one-pot/two-steps chemoenzymatic cascade to access to nitrocyclitols (Scheme 2). 
Aldehydes 4-nitrobutanal (4) and (±)-3-hydroxy-4-nitrobutanal ((±)-6) were used as acceptor substrates in 
aldol addition to DHAP catalysed by Rhu1PATm. When DHAP concentration reached its maximum, the 
aldolase and aldehydes 4 or (±)-6 were added. 
In the first attempt, the aldol addition of DHAP to 4 at 0.1 mmol scale, with a DHAP/nitroaldehyde ratio of 
2:1 at 45 °C failed. Unfortunately, nitroaldehyde 4 was labile at this temperature and induced DHAP 
degradation. Thus, reactions were carried out at 25 ºC. In spite of its hyperthermophile nature, Rhu1PATm 
retains between 5 and 10% of its maximum activity at 25 ºC.[10] In these conditions, aldehyde 4 led to 
nitrocyclitols 5a and 5b and aldehyde (±)-6 led to nitrocyclitols 7a and 7b (Scheme 2). These compounds were 
isolated after purification in 70% and 71% yields for each couple of isomers respectively. These compounds are 
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identical to those previously described.[17] Their configurations were established on the basis of 3R 
stereoselectivity of the enzyme and 1H NMR analysis. 
The stereoselectivity shown by the aldolase depended on the aldehyde acceptor (Table 1). Using the 
aldehyde 4 the major diastereoisomer obtained was the L-threo, which corresponds to the expected 
stereochemical preference for the Rhu1PA (Table 1). 
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Scheme 2. Cascade reactions for the synthesis of nitrocyclitols. First step phosphorylation of DHA catalysed by 
recombinant ATP-dependent DHAK from Citrobacter freundii CECT 4626 (AK=acetate kinase);[18] second step aldol 
reaction catalysed by Rhu1PA and in situ intramolecular Henry reaction; third step hydrolysis of the phosphate group 
using acid phosphatase. Data for Rhu1PAEc, taken from reference [17] 
The data presented in this work were consistent with the ones previously described using Rhu1PAEc as 
catalyst.[17] Using (±)-6 the actual stereoselectivity of Rhu1PATm could not be disclosed. The reaction 
produced 7a and 7b and the enzymatic aldol addition appeared to virtually produce exclusively the L-threo 
diastereoisomer from (R)-6 and the D-erythro from (S)-6 instead of the four possible diastereoisomers (SI 
Scheme S3). This may be explained because an all-equatorial arrangement of substituents (e.g. 7a and almost 
all eq in 7b) corresponds to the more stable product. The remaining mixture of diastereoisomers can then be re-
subjected to further equilibration retroaldol-retro Henry and products 7a and 7b were accumulated.[19]  
This study was continued using the 3,3-diethoxypropanal (8) as an acceptor (Scheme 3). The aldol reaction 
led to the linear compounds 9a and 9b with an isolated yield of 67%. Remarkably, both diastereoisomers L-
threo and D-erythro were obtained in 70:30 ratio for the first time in this work using a rhamnulose-1-phosphate 
aldolase.    
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Scheme 3. Rhu1PATm-catalyzed synthesis of aldol products 9a and 9b, which are putative precursors of nitrocyclitols 
7a and 7b. 
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Products 9a and 9b were previously synthesized using the L-fuculose-1-phosphate aldolase from E. coli 
(Fuc1PAEc).[20] As expected, the percentage obtained from D-erythro diastereoisomer was higher in the 
reactions catalysed by Fuc1PAEc (L-threo:D-erythro ratio 3:97) than when the catalyst was the Rhu1PATm. 
These compounds could be considered as nitrocyclitol precursors. Indeed, deprotection of the aldehyde 
followed by a Henry reaction with nitromethane would lead to nitrocyclitols 7a and 7b. 
Synthesis of iminocyclitols mediated by Rhu1PATm 
The second cascade reaction of the Rhu1PATm, with the DHAK-mediating the DHAP formation was the one 
developed by Clapés’s group for obtaining iminocyclitols (Scheme 4). The strategy consists of the aldol 
addition of DHAP to either (R)- or (S)-N-Cbz-aminoaldehydes. This is followed by an acid phosphatase-
catalysed hydrolysis of the phosphate group and subsequent intramolecular reductive amination by treatment 
with H2 in presence of Pd/C. This strategy allows the formation of three new stereogenic centres for each 
aldehyde tested (Scheme 4):[12a, 21] two of them controlled by the aldolase and one generated during the 
reductive amination.  
First, the capability of the Rhu1PATm to catalyse the aldol addition reaction of DHAP to N-Cbz-
aminoaldehydes was tested on an analytical scale using an N-Cbz-aminoaldehyde:DHAP ratio of 1:1.7. DMF 
(30% v/v) was added to the reaction medium to improve the solubility of the aldehydes. Reaction temperature 
was set up at 45 ºC to retain a good activity of the aldolase, while preventing a high degradation rate of the 
DHAP.[10]  
Reactions were monitored by HPLC and stopped when the formation of aldol adduct was maximal (Table 2), 
thus preventing the spontaneous retroaldol reaction as it has been reported for similar reactions.[21a] In these 
conditions, all the N-Cbz-aminoaldehydes tested were accepted as substrates by Rhu1PATm, which was able to 
use aldehydes with both linear and branched substituent at Cα (Table 2). 
Good conversions (61-74%) were obtained with N-Cbz-aminoaldehydes with small Cα substituents (e.g., 10, 
13a and 13b) (Table 3) and moderate (37-49%) with Cα branched substituents including prolinal derivatives. 
Using the same aldehyde acceptors, Rhu1PAEc at 25 ºC gave similar yields for 10 and 13a,b but required 
longer reaction times (4-5 h).[21a]  For 13c, 13d, 22a and 22b Rhu1PAEc gave superior conversions (58-69% 
conversion).[12a,21c] 
While this ability to accept a wide variety of substituents on the Cα is shared with its mesophilic counterpart 
from E. coli, studies with other DHAP-dependent aldolases demonstrated that not all of them exhibit the same 
degree of tolerance towards structurally diverse N-Cbz-aminoaldehydes.[12a,22,23] 
 
 6 
Rhu1PATm
a)
 
P'ase
 
H+
b)
 
H2
, Pd/C
O
Cbz
N
H
NH
N
OH
HO
HO
OH
HO
HO
NH
OH
HO
HO
N
OH
HO
HO
+
+
++
11
O
∗N
Cbz
N
OH
HO
HO
N
OH
HO
HO
O
*
OH
OH
∗
23
N
Cbz
∗ ∗
N
∗
OH
HO
HO
24-27
53:47
+
12a 12b
15a 16b 17b 18c
24a 25a 26b 27b
65:3560:40
+
O
OPO32
−
OH OH
Cbz
N
H
O
OPO32
−
OH
12
3
4
5
6
2
3
4
5
6
Rhu1PATm
a)
 
P'ase
 
H+
b)
 
H2
, Pd/C
O
14
∗
H
N
OH
∗
∗
H
N
O
OPO32
−
OH
12
3
45Cbz
R1 R1
Cbz
10
∗
∗
H
N∗
HO
OH
R1
13
a: R1
 = CH3
 
(S);
 
b:
 
R1
 = CH3 (R);
 c: R1
 = CH(CH3)2
 
(R);
 
d:
 
CH2CH(CH3)2
 
(S)
19c 20c
HO
H
N Me
HO OH
HO H
N Me
HO OH
HO H
N Me
HO OH
HO H
N
HO OH
HO
Me
Me H
N
HO OH
HO
Me
Me H
N
HO OH
HO
Me
Me H
N
HO OH
HO Me
Me
21d
22
OPO32
−
a)
 
P'ase
 
H+
b)
 
H2
, Pd/C
15-21
a: (S);
 
b:
 
(R)
1
1
Rhu1PATm
1
2
3 4
5
42:25:3267:33
 
Scheme 4. Cascade reaction for the synthesis of iminocyclitols employing Rhu1PATm. 
Table 2. Percentage of aldol adducts (11, 14a-d, and 23a-b) formed at analytical scale reactions catalysed by Rhu1PATm.  
Aldehyde Aldol product 
(%)a) 
Optimum reaction 
time (min)b) 
10 11(51) 15 
13a 14a (61) 20 
13b 14b (74) 30 
13c 14c (39) 60 
13d 14d (49) 10 
22a 23a (37) 10 
22b 23b (38) 30 
a) Percentage of aldol adduct formed determined by HPLC using an external standard method. b) Time at which maximum 
accumulation of aldol adduct was reached. 
After these preliminary studies, reactions for obtaining the corresponding iminocyclitols were scaled up to 
mmol scale (i.e., 2 mmol DHAP; 1.2 mmol aldehyde). Once the reaction reached the maximum aldol adduct 
formed, the unreacted aldehyde was removed and aldol adducts 11, 14a-d, 23a and 23b were treated with acid 
phosphatase. Afterwards, aldols were purified by reverse-phase HPLC, paying special attention to prevent the 
losses of possible diastereoisomers formed during the reaction. Then, aldol adducts were submitted to Cbz 
deprotection/intramolecular reductive amination to afford the corresponding iminocyclitols, following the 
method previously described.[21b] This procedure provided overall yields ranging from 9 to 47% (Table 3). The 
structure and relative stereochemistry of the iminocyclitols were determined by NMR and in all cases were 
consistent with those previously described in the literature.[12a, 21a, 21c, 23] As in previous examples of aldol 
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additions catalysed by DHAP-dependent aldolases, it can be assumed from mechanistic considerations that the 
absolute configuration at C-3 (Scheme 4) (i.e. the stereogenic centre generated from the DHAP donor) will be 
conserved throughout with any DHAP-aldolases and with no exceptions known so far.[5,21,22] Moreover, the 
specific absolute configuration introduced by some N-Cbz-aminoaldehyde chiral center (e.g., 13a-d, 22a and 
22b, Scheme 4) allowed the unequivocal assessment of the absolute stereochemistry of the iminocyclitols. Thus, 
from the stereochemical configuration of the iminocyclitols it was possible to infer the stereochemical outcome 
of both the enzymatic aldol addition and the reductive amination.   
Mixtures of L-threo and D-erythro diastereoisomers were obtained, which depended upon the structure of the 
acceptor aldehyde (Table 3). Rhu1PATm provided a good stereoselectivity for the (S)- configured N-Cbz-
aminoaldehydes furnishing always the L-threo configured aldol adducts while L-threo:D-erythro mixtures were 
formed with the (R)- configured ones (Table 3). This behaviour was similar to that observed for Rhu1PAEc 
using both DHAP or DHA in the presence of borate buffer as donors.[12a, 21a, 22, 23] The aldol addition of DHAP 
to (R)-N-Cbz-valinal (13c) gave a mixture of L-threo:D-erythro (32:68) being the D-erythro the major one 
(Table 3). Interestingly, the same reaction catalysed by Rhu1PAEc was fully D-erythro stereoselective.[12a]  For 
13c both enzymes have a preference for the D-erythro stereochemistry, which is typically obtained with 
Fuc1PAEc catalyst. 
Table 3. Overall yield and stereochemical outcome obtained in the synthesis of iminocyclitols catalysed by Rhu1PATm.  
Aldehyde Iminocyclitol  Iminocyclitol Overall yield 
(%)a) 
L-threo:D-erythro  
(%)b) 
10 12a+12b 32 53:47 
13a 15a 19 >95:5 
13b 16b+17b 47 67:33 
13c 18c+19cc)+20c 18 32:68 
13d 21 12 >95:5 
22a 24a+24b 9 >95:5 
22b 24c+24d 12 65:35 
a) Purification procedures were not optimized. b) Ratio corresponding to the aldol adducts inferred from the iminocyclitol 
compounds and determined within the limits of NMR detection. c) 18c and 19c are epimers at C-2 formed during reductive 
amination. 
In another example, the aldol addition of DHAP to (R)-N-Cbz-prolinal (22b), Rhu1PATm gave a mixture of 
L-threo:D-erythro 65:35, whereas using Rhu1PAEc the reaction was reported to be fully stereoselective.[23] 
Given the high sequence identity and structural homology between the Rhu1PA from T. maritima and E. coli, it 
could be argued that the lack of selectivity in the Rhu1PATm enzyme is determined for similar reasons to those 
already determined for Rhu1PAEc. Thus, according to Kroemer et al.,[24] L-lactaldehyde binds to the catalytic 
centre of the Rhu1PAEc through two hydrogen bonds, directing the methyl group to the hydrophobic 
surroundings. As a result, the substrate is anchored to the active site of the enzyme favouring the nucleophilic 
attack by just one enantiotopic face. Restrictions imposed by the structure of the different N-Cbz-
aminoaldehydes, as well as the lack of the hydroxyl group, may induce an incorrect orientation of the aldehyde 
in the catalytic pocket.[21a] Moreover, some important differences may occur in the active site of both aldolases 
since Rhu1PATm was not able to use DHA in presence of borate buffer, an ability so far restricted to 
Rhu1PAEc.[22] 
As previous studies have reported, stereochemistry of the iminocyclitols at C-2 (C-3 in pyrrolizidines 24-27) 
revealed that the reductive amination with H2 in presence of Pd/C depended on the structure of the aldol adduct 
precursor. For most of the examples, e.g. iminocyclitols 12a-b, 15a, 16b, 17b, 21d, 26b and 27b reductive 
amination was highly diastereoselective. Here, the hydrogenation took place from the face opposite to the C-4 
hydroxyl group (C-1 hydroxyl group for the pyrrolizidine derivatives), regardless of the relative 
stereochemistry of the other substituents. Exceptions were observed in the iminocyclitols 18c, 19c, 24a and 25a. 
Conclusion 
The work presented herein describes the synthetic scope of the Rhu1PATm. Since this aldolase maintains a 
significant percentage of activity at temperatures much lower than its optimum (95 °C), it is compatible with 
multienzyme systems for C-C bond formation involving mesophilic enzymes. This enzyme was successfully 
tested in two different chemo-enzymatic cascades for the synthesis of nitrocyclitols and iminocyclitols. In both 
cases, Rhu1PATm was able to catalyse the aldol addition using the corresponding aldehydes to provide the 
desired products with similar or higher yields than Rhu1PAEc. Additionally, the stereoselectivity shown by the 
aldolase from T. maritima was, in general, similar to the one of the Rhu1PAEc, even though there were 
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significant differences on specific substrates. Our data indicated that the formation of the L-threo isomer was 
faster than that of the D-erythro isomer. No effect of the temperature was observed in this process. 
Aldol adduct precursors of iminocyclitols 14a, 14d and 23a were obtained with full L-threo (3R,4S) 
stereoselectivity. The rest aldol adducts from nitroaldehydes and N-Cbz-aminoaldehydes were obtained as 
mixtures of L-threo (3R,4S) and D-erythro (3R,4R) diastereoisomers. The major diasteromer formed was the 
one with the natural stereopreference of the enzyme (L-threo), with the exception of aldehyde 13c.  
Experimental Section 
Materials  
All solvents and reagents were purchased from Sigma-Aldrich or Acros. Triosephosphate isomerase (TIM), α-
glycerophosphate dehydrogenase (αGDH), phosphatase acid from potato and acetate kinase (AK) was purchased from 
Sigma-Aldrich. Rhu1PA from T. maritima and DHAK from C. freundii were expressed and purified as previously 
described.[10, 18] DHAP was enzymatically prepared from DHA as previously described by Oroz-Guinea et al.[11c] with 
slight modifications. Acetyl phosphate (7.15 mmol), MgSO4 (1.25 mmol) and DHA (5 mmol) were added to phosphate 
buffer (30 mL; 60 mM; pH=7.5) and water to a final reaction volume of 90 mL. DHAK (431 U) and AK (225 U) were 
suspended in ultra-pure water (pH ≈ 7.0) and added to the reaction. To start the reaction ATP (163 µmol) was added. The 
phosphorylation reaction was completed after 30 minutes. For the storage of the mixture the pH was adjusted to 5.0 to 
avoid the degradation of DHAP and was subsequently frozen. Nickel/iminodiacetic acid (Ni2+/IDA) agarose was supplied 
by Agarose Bead Technologies (Spain). Dialysis was performed in SPECTRA/Por® membranes (Spectrum) with 12,000-
14,000 Da cut-off. 
Rhu1PATm activity assay  
The retro-aldol activity of Rhu1PATm was spectrophotometrically measured using rhamnulose-1-phosphate (Rhu-1P) as 
substrate. Rhu-1P was synthesized using the multienzyme system described by Sánchez-Moreno et al.[11a] at 1 mmol of 
DHA scale. The reaction was carried out in 30 mL of HEPES buffer (20 mM; pH 7.5) containing DHA (1 mmol), L-
lactaldehyde (1.5 mmol), acetyl phosphate (2 mmol), ATP (68 pmol), MgSO4 (250 pmol), ZnCl2 (0.3 pmol), DHAK (15 
U), AK (30 U) and Rhu1PA from E. coli. Activity assays were run at 45 ºC following the decrease in absorbance at λ=340 
nm (εNADH=6220 M-1cm-1) for 10 min in a reaction mixture (1 mL) containing Tris-HCl buffer (40 mM; pH 8.0), NADH 
(0.2 mmol), αGDH/TIM (2.4 U of αGDH and 24.8 U of TIM), Rhu-1P (10 μmol), and Rhu1PATm. 1 unit aldolase activity 
was defined as the amount of enzyme that converts 1 µmol of Rhu-1P in DHAP and L-lactaldehyde per minute in the 
above described conditions. 
Stereochemistry study of the Rhu1PATm catalysed reaction 
Stereochemistry of the Rhu1PATm was evaluated by measuring the percentage of each diasteroisomer formed depending 
on the reaction time and temperature. Benzyloxyacetaldehyde 2 (100 μmol) was dissolved into 600 μL of DMSO (10% 
final volume) and, then, added to 200 μmol of DHAP. Afterwards, the reaction pH was adjusted to 6.9. Finally, aldolase 
(0.4 U) was added to start the reaction. Four different temperatures were chosen to carry out the study: 4 ºC, r.t, 45 ºC and 
80 ºC. Aliquots of each reaction were taken at different times and formation of the diasteroisomer was monitored by HPLC, 
using a RP-HPLC XBridge® C18, 5 μm, 4.6 x 250 mm column (Waters). The elution system used was: solvent (A); 0.1% 
trifluoroacetic acid (TFA) in H2O (v/v) and solvent (B); 0.095% (v/v) TFA in CH3CN/H2O 4:1; gradient elution from 10% 
to 70% B over 30 min. Flow rate was 1 mL min-1, detection was at 215 nm. The amount of aldol adduct produced was 
quantified from the peak areas using an external standard.  
Synthesis of nitrocyclitols 5a, 5b, 7a and 7b and nitrocyclitol precursors 9a and 9b. 
Nitroaldehyde 4 was prepared mixing acrolein with a excess of nitromethane with KF as a mild base at -35 ºC, as 
described by El Blidi et al.[16a] Nitroaldehyde (±)6 was obtained starting from aldehyde 8, as reported by El Blidi et al.[16b] 
Finally, aldehyde 8 was prepared by ozonolysis of the corresponding alkene,[25] previously obtained using the procedure of 
Hoaglin et al.[26]  
0.5 mmol of the corresponding aldehyde —4 (58.5 mg), (±)6 (66.5 mg) or 8 (73.1 mg)— and 3 U of Rhu1PATm were 
added to 1 mmol of DHAP, previously adjusted to pH 6.9. Distilled water was added to a final volume of 30 mL. DMSO 
(10% in the final volume) was added to the reaction media to dissolve aldehyde 4. The reaction was kept at room 
temperature for 24 h with stirring. The pH was then adjusted to 4.7 with HCl (1M) and Rhu1PATm was eliminated by 
centrifugation. Subsequently, acid phosphatase from potato (200 U) was added and the reaction was carried out during 24 
h. After this time, the phosphatase was removed and the resulting solution was concentrated under vacuum. Reactions 
were monitored spectrophotometrically measuring the disappearance of DHAP[11b] and by TLC (Merck 60 F254 silica gel 
TLC plates). The residue was purified by column chromatography with Merck 60/230-400 and 60/40-63 mesh silica gel, 
using a solvent gradient from 9:1 to 8:2 of CH2Cl2/MeOH to afford the nitrocyclitols 5a-b, and 7a-b and 95:5 of 
CH2Cl2/MeOH for the ketone diacetal 9a-b. Overall yields of the desired products were: 5a+5b (72 mg, 70%), 7a+7b 
(79.2 mg, 71%) and 9a+9b (77.1 mg, 67%). 1H and 13C NMR spectra of these products were recorded on a Bruker Avance 
400 spectrometer in CDCl3, D2O, and CD3OD. In all cases, resonance spectra were consistent with those previously 
described for these compounds.[17, 19]  
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1-(Hydroxymethyl)-6-nitrocyclohexane-1,2,3-triol: 2 isomers. (2R,3S):(2R,3R) ratio 5a:5b, 95:5. 
Isomer (1R,2R,3S,6S) 5a: 1H NMR (400 MHz, MeOD, 298 K): δ 4.79 (dd, J= 13.0 Hz, J=4.0 Hz, 1H, H-6), 3.82 (d, J=11 
Hz, 1H, H-7B), 3.73 (ddd, J=9 Hz, J=11.5 Hz, J=4.6 Hz, 1H, H-3), 3.37 (d, J=9.3 Hz, 1H, H-2), 3.33 (d, J=11.0 Hz, 1H, 
H-7A), 2.43 (m, 1H, H-5), 2.01 (m, 1H, H-5), 1.97 (m, 1H, H-4 B), 1.32 (m, 1H, H-4 A). 
Isomer (1R,2R,3R,6S) 5b: 1H NMR (400 MHz, MeOD, 298 K): δ 4.75 (dd, J=12.4 Hz, J=4.0 Hz, 1H, H-6), 4.00 (m, 1H, 
H-3), 3.88 (d, J=2.6 Hz, 1H, H-2), 3.83 (d, J=11.5 Hz, 1H, H-7B), 3.55 (d, J=11.5 Hz, 1H, H-7A), 2.41 (m, 1H, H-5), 1.93 
(m, 2H, H-5, H-4B), 1.76 (m, 1H, H-4A). 
1-(Hydroxymethyl)-6-nitrocyclohexane-1,2,3,5-tetraol: 2 isomers. (2R,3S):(2R,3R) ratio 7a:7b, 75:25. 
Isomer (1R,2R,3S,5R,6S) 7a: 1H NMR (400 MHz, MeOD, 298 K): δ 4.67 (d, J=10.6 Hz, 1H, H-6), 4.50 (ddd, J=11.0 Hz, , 
J=11.0 Hz, , J=4.9 Hz, 1H, H-5), 3.86 (m, 1H, H-3), 3.77 (d, , J=11.2 Hz, 1H, H-7B), 3.41 (d, J=9.5 Hz, 1H, H-2), 3.24 (d, 
J=10.8 Hz, 1H, H-7A), 2.26 (m, 1H, H-4B), 1.41 (pq, J=12.1 Hz, J=12.1 Hz, J=12.1 Hz, 1H, H-4A). 
Isomer (1R,2R,3R,5R,6S) 7b: 1H NMR (400 MHz, MeOD, 298 K): δ 4.55 (d, J=10.6 Hz, 1H, H-6), 4.43 (ddd, J=11.0 Hz, 
J=11.0 Hz, , J=4.9 Hz, 1H, H-5), 4.06 (m, 1H, H-3), 3.82 (d, J=2.4 Hz, 1H, H-2), 3.79 (d, J=11.3 Hz, 1H, H-7B), 3.50 (d, 
J=11.3 Hz, 1H, H-7A), 2.02 (m, 1H, H-4B), 1.82 (ddd, J=11.9 Hz, J=11.9 Hz, J=10.8 Hz, 1H, H-4A). 
6,6-Diethoxy-1,3,4-trihydroxyhexan-2-one: 2 isomers. (3R,4S):(3R,4R) ratio 9a:9b, 70:30. 
Isomer (3R,4S) 9a: 1H NMR (400 MHz, CD3OD, 298 K): δ 4.66 (dd, 1H, J=4.5 Hz y J=6.8 Hz, H-6), 4.50 (d, 1H, J=19.4 
Hz, H-1A) 4.40 (d, 1H, J=19.4 Hz, H-1B), 3.88 (m, 1H, H-3), 3.59 (m, 4H, OCH2-7, OCH2-9), 3.27 (m, 1H, H-4), 1.82 (m, 
2H, CH2-H5), 1.15 (m, 6H, CH3-8, CH3-10); 13C NMR (100 MHz, CD3OD, 298 K): δ 213.47 (C-2), 102.38 (C-6), 79.67 
(C-3), 70.29, 67.95, 63.29, 62.72 (C-1, C-4, C-7, C-9), 38.57 (C-5), 15.66 (C-8, C-10). 
Isomer (3R,4R) 9b: 1H NMR (400 MHz, CD3OD, 298 K): δ 4.69 (dd, 1H, J=4.1 Hz y J=7.5 Hz, H-6), 4.48 (d, 1H, J=19.4 
Hz, H-1A) 4.37 (d, 1H, J=19.4 Hz, H-1B), 4.05 (m, 6H, H-3, H-4, OCH2-7, OCH2-9), 1.77 (m, 2H, CH2-H5), 1.15 (m, 6H, 
CH3-8 CH3-10); 13C NMR (100 MHz, CD3OD, 298 K): δ 212.94 (C-2), 102.25 (C-6), 79.77 (C-3), 70.89, 68.12, 63.02, 
62.80 (C-1, C-4, C-7, C-9), 37.79 (C-5), 15.66 (C-8 , C-10). 
Analytical scale synthesis of iminocyclitols 
Analytical scale reactions (1 mL total volume) were conducted in 2 mL test tubes with screw cap incubated at 45 ºC. 15 
μmol of aldehyde —10, 13a and 13b (3.1 mg each); 13c (3.5 mg); 13d (3.74 mg); 22a and 22b (3.49 mg each)— was 
dissolved in DMF (300 μL) and then mixed with freshly prepared DHAP neutralized at pH 6.9. Reaction was started by 
adding the aldolase (between 0.75 and 1.6 U measured at 45 ºC). Reactions were monitored by HPLC, as described above. 
To monitor those reactions with aldehydes 13c and d, 22a and 22b the gradient elution was changed to 30% to 100% B 
over 30 min.  
Preparative scale synthesis of iminocyclitols  
The general procedure for the production of the aldols 11, 14 and, 23 was as described above, with only slight variations 
on the stoichiometry: 1.2 mmol of the corresponding aldehyde—10, 13a and 13b (249 mg each); 13c (282 mg), 13d (299 
mg); 22a and 22b (278 mg each)— was dissolved in 24 mL of DMF (35% of final volume), followed by the addition of 
distilled water (until a final volume of 70 mL), 2 mmol of DHAP (previously synthesized and adjusted to pH 6.9) and 10 U 
of Rhu1PATm. The reaction progress was followed spectrophotometrically, measuring the aldol formed by retro-aldol 
reaction catalysed by Rhu1PA from E. coli. When a maximum of phosphorylated aldol conversion was achieved, 2 
volumes of MeOH were added to stop the reaction and precipitate the enzyme (10: 105 min; 13a: 90 min; 13b: 75 min; 
13c: 150 min; 13d: 150 min; 22a: 60 min; 22b: 90 min). Then, the mixture was filtered through a 0.45 mm cellulose 
membrane filter and MeOH was removed under vacuum. The filtrate was washed with AcOEt (3x100 mL) to remove the 
aldehyde that did not react.  
Afterwards, the aqueous phase was acidified (pH 4.7) and phosphatase acid from potato was added (5.3 U per mmol of 
phosphorylated product). Dephosphorylation reaction was followed by HPLC using the same methodology as described 
above. When the product was completely dephosphorylated the reaction was stopped by adding two volumes of MeOH. 
After removal of the enzyme by filtration, the filtrate was adjusted to pH 3.0 and loaded onto a semi-preparative HPLC 
column X-Terra® (19/250 mm). Products were eluted using CH3CN gradient. The flow rate was 10 mL min-1 and the 
products were detected at 215 nm. Fractions containing the pure product were pooled and lyophilized. Overall yields of the 
desired products were: 12a+12b (112.8 mg, 32 %), 15a (68.9 mg, 19%), 16b+17b (168.2 mg, 47%), 18c+19c+20c (70.0 
mg, 18%), 21d (48.1 mg, 12%), 24a+25a (36.5 mg, 9%), 26b+27b (48.0 mg, 12%).  
The product obtained was dissolved in H2O/MeOH (1:1 v/v) and treated with H2 (50 psi) in the presence of Pd/C (2 eq. 
w/w) at room temperature during 24 h. After that, the catalyst was removed and the filtrate was adjusted to pH 6.4 with 
formic acid and lyophilized obtaining a solid material.  
Separation of the isomers of iminocyclitols 16b+17b, 18c+19c+20c and 26b+27b was performed in a FPLC system using 
CM-Sepharose CL-6B (Amersham Pharmacia) packed in a glass column (45 x 25 cm). The column was washed with four 
volumes (1vol ~ 220 mL) of a 100 mM solution of NH3 and then equilibrated with four additional volumes of distilled 
H2O (pH ~ 7.0). Iminocyclitols were dissolved in 10 ml of H2O and the pH of the solution adjusted to 6.0 with formic acid 
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to be loaded in the column. The column was washed with three volumes of distilled H2O (pH ~ 7.0) and the products were 
eluted with a 10 mM solution of NH3 at a flow of 1 ml min-1.  
Fractions containing the compounds were analysed by NMR. 1H and 13C NMR iminocyclitols spectra were recorded on a 
Varian System 400 spectrometer. The compounds described were fully characterized using typical gradient-enhanced 2D 
experiments: COSY, HSQC, recorded under routine conditions (see the Supporting Information for spectra). 
2-(Hydroxymethyl)piperidine-3,4-diol: 2 isomers. (2S,3S,4S):(2S,3S,4R) ratio 12a+12b 53:47. 
Isomer (3S,4S) 12a: 1H NMR (400 MHz, D2O, 298 K): δ 3.87 (dd, J=3.2, J=12.6 Hz, 1H, H-7A), 3.73 (dd, J=5.7 Hz, 
J=12.7 Hz, 1H, H-7B), 3.6 (dt, J=4.9 Hz, J=9.5 Hz, J=11.6 Hz, 1H, H-4), 3.13 (t, 1H, H-3), 3.0 (br, 1H, H-6A), 3.0 (m, 1H, 
H-2), 2.95 (dt, J=3.2 Hz, J=13.1 Hz, 1H, H-6B), 1.91 (br, 1H, H-5A), 1.38 (dq, J=4.3 Hz, 1H, H-5B). 13C NMR (125 MHz, 
D2O, 298 K): δ 72.38 (C-4), 72.11 (C-3), 60.57 (C-7), 60.45 (C-2), 44.38 (C-6), 31.44 (C-5). 
Isomer (3S,4R) 12b: 1H NMR (400 MHz, D2O, 298 K): δ 4.0 (m, 1H, H-3), 3.80 (m, 1H, H-4), 3.2 (m, 1H, H-2), 1.85 (m, 
1H, H-5A), 1.75 (m, 1H, H-5B), 3.76 (dd, 1H, H-7A), 3.72 (dd, 1H, H-7B), 3.18 (m, 1H, H-6A), 2.95 (m, 1H, H-6B). 13C 
NMR (125 MHz, D2O, 298 K): δ 68.26 (C-4), 66.45 (C-3), 60.17 (C-7), 59.65 (C-2), 42.40 (C-6), 25.13 (C-5). 
(5S)-2-(Hydroxymethyl)-5-methylpyrrolidine-3,4-diol (15a). 
1H NMR (400 MHz, D2O, 298 K): δ 3.77 (t, J=7.0 Hz, 1H, H-3), 3.66 (dd, J=4.2 Hz, J=12.0 Hz, 1H, H-7A), 3.60 (t, J=7.5 
Hz, 1H, H-4), 3.58 (dd, J=6.4 Hz, J=12.0 Hz, 1H, H-7B), 3.13 (dt, J=4.2 Hz, J=6.4 Hz, J=7.0 Hz, 1H, H-2), 3.06 (dq, 
J=7.0 Hz, 1H, H-5), 1.16 (d, J=7.0 Hz, 3H, H-6). 13C NMR (125 MHz, D2O, 298 K): δ 81.15 (C-4), 76.53 (C-3), 61.67 (C-
2), 60.65 (C-7), 56.28 (C-5), 15.95 (C-6). 
(5R)-2-(Hydroxymethyl)-5-methylpyrrolidine-3,4-diol 2 isomers. (2S,3S,4S,5R):(2S,3S,4R,5R) ratio 16b:17b 67:33. 
Isomer (2S,3S,4S,5R) 16b: 1H NMR (400 MHz, D2O, 298 K): δ 4.01 (dd, J=1.4 Hz, J=3.2 Hz, 1H, H-4), 3.95 (dd, J=1.8 
Hz, J=3.2 Hz, 1H, H-3), 3.84 (dd, J=4.9 Hz, J=11.9 Hz, 1H, H-7A), 3.48 (dq, J=3.5 Hz, J=6.5 Hz, 1H, H-5), 3.71 (dd, 
J=8.8 Hz, J=12.3 Hz, 1H, H-7B), 3.16 (dt, J=3.3 Hz, J=5.1 Hz, J=8.2 Hz, 1H, H-2), 1.24 (d, J=6.7 Hz, 3H, H-6). 13C NMR 
(125 MHz, D2O, 298 K): δ 76.3 (C-4), 76.3 (C-3), 67.5 (C-2), 59.6 (C-7), 56.51 (C-5), 11.8 (C-6). 
Isomer (2S,3S,4R,5R) 17b: 1H NMR (400 MHz, D2O, 298 K): δ 4.28 (t, J=3.7 Hz, 1H, H-3), 3.95 (dd, J=3.7 Hz, J=9.0 Hz, 
1H, H-4), 3.9 (dd, J=4.7 Hz, J=11.8 Hz, 1H, H-7A), 3.8 (dd, J=8.4 Hz, J=11.8 Hz, 1H, H-7B), 3.58 (m, J=3.7 Hz, J=4.7 Hz, 
J=8.4 Hz, 1H, H-2), 3.31 (m, 1H, H-5), 1.32 (d, J=6.7 Hz, 3H, H-6). 13C NMR (125 MHz, D2O, 298 K): δ 76.7 (C-4), 70.4 
(C-3), 61.5 (C-2), 58.4 (C-7), 55.5 (C-5), 16.06 (C-6). 
2-(Hydroxymethyl)-5-isopropylpyrrolidine-3,4-diol 3 isomers. (2R,3R,4S,5R):(2R,3R,4S,5S):(2R,3S,4S,5R) ratio 
18c:19c:20c, 42:25:32. 
Isomer (2R,3R,4S,5R) 18c: 1H NMR (400 MHz, D2O) δ 4.22 (t, J = 3.9 Hz, 1H), 4.13 (dd, J = 8.5, 4.3 Hz, 1H), 3.88 (dd, J 
= 11.5, 6.3 Hz, 1H), 3.75 (dd, J = 11.4, 7.1 Hz, 1H), 3.47 (td, J = 6.7, 3.6 Hz, 1H), 3.01 (m, 1H), 1.89 (dq, J = 13.7, 6.8 Hz, 
1H), 1.03 (d, J = 6.8 Hz, 3H), 1.01 (d, J = 6.7 Hz, 3H). 13C NMR (100 MHz, D2O): δ 71.4 (C-3), 74.2 (C-4), 65.8 (C-5 ), 
60.4 (C-2), 59.9 (C-6), 29.9 (C-7), 19.6 (C-8), 18.3 (C-9). 
Isomer (2R,3S,4S,5R) 19c: 1H NMR (400 MHz, D2O) δ 4.13 (d, J = 4.7 Hz, 1H), 4.00 (dd, J = 2.8, 0.9 Hz, 1H), 3.82 (dd, J 
= 11.6, 5.6 Hz, 1H), 3.74 (m, 1H), 3.23 (ddd, J = 7.0, 5.6, 2.8 Hz, 1H), 3.01 (m, 1H), 1.97 (m, 1H), 1.01 (d, J = 3.1 Hz, 
3H), 1.00 (d, J = 3.1 Hz, 3H). 13C NMR (101 MHz, D2O) δ 74.7 (C-3), 74.6 (C-4) , 68.2 (C-5), 62.3 (C-2), 58.0 (C-6), 25.7 
(C-7), 18.7 (C-8), 18.4 (C-8). 
Isomer (2R,3S,4S,5R) 20c: 1H NMR (400 MHz, D2O, 298 K): δ 4.21 (t, J=4.0 Hz, 1H, H-3), 4.12 (m, 1H, H-4), 3.95 (dd, 
J=11.5 Hz, J=5.0 Hz, 1H, H-6A), 3.74 (dd, J=11.2 Hz, J=7.4 Hz, 1H, H-6B), 3.46 (dt, J=3.6 Hz, J=3.1 Hz, 1H, H-2), 3.00 
(t, J=8.0 Hz, 1H, H-5), 1.88 (dt, J=6.8, 1H, H-7), 1.00 (m, 6H, H-8, H-9). 13C NMR (100 MHz, D2O): δ 76.2 (C-4), 73.4 
(C-3), 68.7 (C-5), 64.1 (C-2), 60.2 (C-6), 32.0 (C-7), 21.4 (C-8), 20.5 (C-9). 
2-(Hydroxymethyl)-5-isobutylpyrrolidine-3,4-diol (21d). 
1H NMR (400 MHz, D2O, 298 K): δ 3.93 (t, J=6.9 Hz, 1H, H-3), 3.83 (m, 1H, H-4), 3.78 (m, J=12.6, 3.9 Hz, 1H, H-6A), 
3.83 (m, J=12.7, 6.0 Hz, 1H, H-6B), 3.25 (m, 1H, H-2), 3.20 (m, 1H, H-5), 1.71 (m, 1H, H-8), 1.59 (m, 1H, H-7A), 1.56 (m, 
1H, H-7B), 0.94 (m, 6H, H-9, H-10). 13C NMR (100 MHz, D2O): δ 80.4 (C-4), 76.3 (C-3), 61.5 (C-2), 60.5 (C-5), 58.5 (C-
6), 41.4 (C-7), 24.4 (C-8), 22.4 (C-9), 20.9 (C-10). 
(7aS)-3-(Hydroxymethyl)hexahydro-1H-pyrrolizine-1,2-diol: 2 isomers. (1S,2S,3S,7aS):(1R,2S,3S,7aS) ratio 24a:25a, 
60:40.  
Isomer (1S,2S,3S,7aS) 24a: 1H NMR (400 MHz, D2O, 298 K): δ 3.79 (m, J=12.2 Hz, J=8.2 Hz, 1H, H-8A), 3.78 (bs, 1H, 
H-2), 3.74 (t, J=8.0 Hz, 1H, H1), 3.65 (m, J=11.8, 6.5 Hz, 1H, H-8B), 3.20 (m, 1H, H-7a), 2.94 (bs, 1H, H-5A), 2.80 (m, 
1H, H-5B), 2.75 (m, 1H, H-3), 1.96 (m, 1H, H-7A), 1.88 (m, 1H, H-6A), 1.79 (m, 1H, H-6B), 1.76 (m, 1H, H-7B). 13C NMR 
(100 MHz, D2O): δ 79.5 (C-1), 77.5 (C-2), 69.2 (C-3), 66.6 (C-7a), 55.8 (C-8), 54.8 (C-5), 29.3 (C-7), 24.3 (C-6). 
Isomer (1R,2S,3S,7aS) 25a: 1H NMR (400 MHz, D2O, 298 K): δ 4.33 (dd, J=3.8 Hz, J=1.5 Hz, 1H, H-2), 4.26 (bt, J=1.9 
Hz, 1H, H-1), 4.08 (m, 2H, H-8A, H-8B), 4.02 (m, 1H, H-3), 3.93 (m, 1H, H-7a). 3.50 (m, 2H, H-5A, H-5B), 2.41 (m, 1H, 
H-7A), 2.23 (m, 1H, H-6A), 1.87 (m, 2H, H-7B, H-6B). 13C NMR (100 MHz, D2O): δ 78.5 (C-1), 77.5 (C-2), 74.8 (C-3), 
65.8 (C-7a), 55.8 (C-8), 50.1 (C-5), 28.9 (C-7), 25.8 (C-6). 
 11 
(7aR)-3-(Hydroxymethyl)hexahydro-1H-pyrrolizine-1,2-diol: 2 isomers. (1S,2S,3S,7aR):(1R,2S,3R,7aR) ratio 26b:27b, 
65:35.  
Isomer (1S,2S,3S,7aR) 26b: 1H NMR (400 MHz, D2O, 298 K): δ 4.04 (dd, J=6.3, 1.4 Hz, 1H, H-1), 3.83-3.73 (m, 4H, H-2, 
H-7a, H-8A, H-8B), 3.13 (m, 1H, H-3), 3.04 (m, 1H, H-5A), 2.83 (dt, J=6.2 Hz, J=4. 3 Hz, 1H, H-5B), 1.89 (bs, 1H, H-6A), 
1.79 (m, 2H, H-7A, H-7B), 1.65 (m, 1H, H-6B). 13C NMR (100 MHz, D2O): δ 75.9 (C-2), 72.9 (C-1), 65.8 (C-7a), 64.6 (C-
3), 58.8 (C-8), 54.6 (C-5), 26.9 (C-6), 22.8 (C-7). 
Isomer (1R,2S,3R,7aR) 27b: 1H NMR (400 MHz, D2O, 298 K): δ 4.27 (dd, J=3.6, 1.6 Hz, 1H, H-1), 3.94 (dd, J=4.4 Hz, 
J=1.5 Hz, 1H, H-2), 3.87 (m, 1H, H-7a), 3.70 (m, J=11.2 Hz, J=6.5 Hz, 1H, H-8A), 3.45 (m, 1H, H-8B), 3.00 (m, 1H, H-
5A), 2.91 (m, 1H, H-3), 2.78 (m, 1H, H-5B), 1.97 (m, 1H, H-6A), 1.87 (m, 1H, H-7A), 1.82 (m, 2H, H-6B, H-7B).13C NMR 
(100 MHz, D2O): δ 77.9 (C-2), 74.2 (C-1), 70.3 (C-7a), 69.4 (C-3), 58.8 (C-8), 56.6 (C-5), 29.5 (C-6), 25.4 (C-7). 
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